Malaria Clinical Trial
Official title:
Impact of Host Iron Status and Iron Supplement Use on Growth and Viability of the Erythrocytic Stage of Plasmodium Falciparum
The purpose of this study is to perform laboratory based studies to determine if the growth
and development of the malaria parasite is effected by iron status of its host (the person
infected with the malaria parasite). Iron deficiency affects over 500 million people
including many pregnant women and children from areas of the world that are plagued by
malaria. Some population based studies have suggested that iron deficiency protects people
from getting malaria and this has raised questions about the wisdom of public health
policies that provide universal iron supplementation in countries where malaria is common.
We will use red blood cells and sera from patients with iron deficiency anemia, hereditary
hemochromatosis and normal individuals who are taking iron supplements to look at this
question in a very systematic way. This study should provide information for or against a
possible mechanism by which iron deficiency may affect the malaria parasite. The results
will contribute to efforts to develop evidence-based public health policies on iron
supplementation policies in malaria-endemic areas.
There are three different types of individuals involved in this study (1) people with iron
deficiency anemia who will be taking iron supplementation (2) people without iron deficiency
anemia who will be taking iron supplementation and (3) people with a condition called
hereditary hemochromatosis who have an excess of iron in their bodies.
Purpose: This proposal is aimed at studying the effect of an individual's iron status and
iron supplementation on the growth and viability of the malarial parasite Plasmodium
falciparum. The overall goal is to provide evidence to support the development of
evidence-based programs to improve global health policy on iron supplementation in areas of
the world with high malaria transmission. Current WHO recommendations include routine
supplementation of women and children. Recently however, the wisdom of this policy when
applied to areas afflicted with high rates of malaria has come under scrutiny. This proposal
will study the effects of red blood cells (RBCs) and sera from iron overloaded patients
(with hereditary hemochromatosis), iron deficient patients, and iron replete individuals
taking oral iron supplements. This proposal will attempt to identify the mechanism by which
the human host's iron status and iron supplement use affects the growth and viability of the
P. falciparum parasite in red blood cells.
Participants: Healthy adult volunteers, adults with iron deficiency anemia, and patients
with hereditary hemochromatosis will be enrolled in this study. Fifteen individuals will be
recruited under each of the above three settings. This study involves only subjects over 18
years of age and both males and females will be included.
Procedures (methods): Participation in the study involves undergoing a series of screening
tests and donation of blood and either a single time point (for hemochromatosis patients) or
a total of three pre-specified time points (for healthy volunteers and those with iron
deficiency). The healthy individuals will be asked to take oral iron supplements once daily
(325 mg ferrous sulfate) for the duration of this study. Patient's blood will be separated
by centrifugation into RBCs and sera, both of which will be used for in vitro studies on the
impact of iron status on the growth and viability of Plasmodium falciparum.
;
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
| Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
| Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
| Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
| Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
| Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
| Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
| Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
| Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
| Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
| Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
| Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
| Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
| Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
| Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
| Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
| Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
| Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
| Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
| Completed |
NCT02605720 -
Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns
|
Phase 3 |